True. But, the results of CD12, if they "trend" to success as is, could still be enough for approval (if we were Gilead or other BP who were "trending" and got EUA.)
One other thought, the recommended 60 day should not affect CD12 since is was completed before the new 60 day recommendation. This would help other trials who are having trouble meeting stat sig. But if leronlimab did it in 28 days (I was hoping they would follow the advise/recommendation of 42 days), the new guidelines would be a mute point for CD12. IF they hit stat sig in fewer days, it would show how well leronlimab works. It will be interesting to follow if this is what Cytodyn and FDA are discussing.
News 
Market Data 
Discover 
